AIKO Biotechnology Secures $1,200,000 Series A Financing
- Feed Type
- Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=b164c1d0-616b-4ecd-a1f3-5daf78addf96&Preview=1 - Date
12/8/2009 - Company Name
AIKO Biotechnology - Mailing Address
2 Union Street Portland, ME 04101 - Company Description
AIKO Biotechnology, Inc. (“AIKO”) is an early stage drug discovery company founded to characterize and validate therapeutic candidates for the management of pain, addiction and adverse side effects resulting from prescription opioid pain reliever use. AIKO’s lead drug candidates will significantly increase the safety and efficacy of opioids that are used by millions of pain sufferers and will offer safer, more effective treatments for opioid overdose and various addictions than any compounds currently available. - Website
http://www.aikobiotech.com - Transaction Type
Venture Equity - Transaction Amount
$1,200,000 - Transaction Round
Series A - Proceeds Purposes
The capital primarily will be used to complete a second human clinical trial using the FDA’s exploratory IND mechanism and continue research on AIKOs promising portfolio of compounds. - M&A Terms
- Venture Investor
Small Enterprise Growth Fund - Venture Investor
Supply Chain Ventures - Venture Investor
Action Equity
